ACR Releases 2024 Guideline Summary for Lupus Nephritis
Nov 25, 2024 · The American College of Rheumatology (ACR) has released a summary of a new guideline for the screening, treatment, and management of lupus nephritis (LN), emphasizing prompt diagnosis, personalized treatment approaches, and …
FDA Roundup: Rheumatology Drug Alerts 2024
Mar 5, 2024 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.
American College of Rheumatology Releases Updated Guidelines …
Jun 18, 2021 · The American College of Rheumatology (ACR) recently released updated guidelines for the pharmacologic management of rheumatoid arthritis (RA). The full report has been published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.. Overall, the updated guidelines include treatment with disease-modifying antirheumatic drugs (DMARDs), including biologic DMARDs (bDMARDs) and ...
Lorecivivint Shows Promising Efficacy for Managing Knee …
Nov 19, 2024 · Lorecivivint (LOR) demonstrated significant efficacy and safety for managing symptoms of moderate to severe knee osteoarthritis (OA) and improving patient reported outcomes (PROs), according to study results presented at the American College of Rheumatology (ACR) Convergence 2024, held from November 14 to 19, in Washington, DC.
Calcium Pyrophosphate Deposition Disease (CPPD)
Oct 5, 2022 · History and Epidemiology. Calcium pyrophosphate deposition disease (CPPD) is a crystal deposition arthropathy that involves the synovial and periarticular tissues, 1 often characterized by painful swelling in one or more joints. 2 Other names that have been traditionally used for CPPD are chondrocalcinosis, pyrophosphate arthropathy, and most especially, pseudogout. 3 It is commonly known as ...
Zasocitinib Is Safe, Effective in Treating Moderate to Severe Plaque ...
Sep 30, 2024 · Zasocitinib demonstrates effectiveness and safety in the treatment of moderate to severe plaque psoriasis, according to study results published in JAMA Dermatology.. Researchers performed a phase 2b, randomized, multicenter, double-blind, placebo-controlled trial that enrolled patients with moderate to severe plaque psoriasis from 55 centers in the United States and Canada to assess the ...
Updated 2019 ACR Recommendations for Treatment of …
Sep 9, 2019 · Based on new evidence and an expert consensus, the American College of Rheumatology (ACR), the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network released updated recommendations for the treatment of axial spondyloarthritis (SpA), which comprises ankylosing spondylitis (AS) and …
Finding Grace While Living With Rheumatoid Arthritis
Oct 4, 2024 · After returning home, King received physical and occupational therapy nearly every other day, in an effort to regain her mobility. Eventually, she began doing her own research in the hopes of finding another provider to help her reach a diagnosis.
Facet Hypertrophy | Diagnosis & Disease Information
Sep 12, 2022 · Etiology and Risk Factors. Spondylosis, or degeneration of the spine, is the most common cause of facet joint disease. Osteoarthritis, or degeneration that is due to natural wear and tear, is a process that involves cytokines and proteolytic enzymes. Other causes of facet hypertrophy can include trauma caused by car accidents, sports injuries, or falls. 1
Metformin Shows Promise for Reducing Symptoms of Sjögren …
Nov 21, 2024 · Metformin may improve salivary gland function and reduce ocular symptoms among patients with Sjögren syndrome, according to study results presented at the American College of Rheumatology (ACR) Convergence 2024, held from November 14 to 19, in Washington, DC.. Sjögren syndrome is a systemic autoimmune disorder marked by lymphocytic infiltration of the exocrine glands, leading to symptoms ...